Type III interferons (IFN-lambdas, IFN-λs) are important antiviral cytokines that can also modulate immune responses by acting through a heterodimeric receptor composed of the specific and limited expressed IFN-λR1 chain and the ubiquitous IL-10R2 chain, which is shared with IL-10 family cytokines. Conflicting data have been reported regarding which cells express the IFN-λR1 subunit and directly respond to IFN-λs. This is, in part, owing to transcript levels of the IFN-λR1 gene, IFNLR1, not always correlating with cell surface protein levels. In this study, we tested a panel of novel monoclonal antibodies (mAbs) that specifically recognize human IFN-λR1. Initially, antigen specificity was confirmed by enzyme-linked immunosorbent assay (ELISA), from which a subset of antibodies was selected for additional flow cytometry and neutralization assays. We further characterized two antibodies based on their strong ELISA binding activity (HLR1 and HLR14) and found only HLR14 could reliably detect cell surface IFN-λR1 protein on a variety of cell lines by flow cytometry. HLR14 could also detect IFN-λR1 protein on certain primary human blood cells, including plasmacytoid dendritic cells and B cells from peripheral blood. Availability of the HLR14 mAb will enable the quantification of IFN-λR1 protein levels on cells and better characterization of the cell specificity of the IFN-λ response.
Get full access to this article
View all access options for this article.
References
1.
AnkN, WestH, BartholdyC, et al.Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol, 2006; 80(9):4501–4509; doi: 10.1128/JVI.80.9.4501-4509.2006
2.
AricescuAR, LuW, JonesEY. A time- and cost-efficient system for high-level protein production in mammalian cells. Acta Crystallogr D Biol Crystallogr, 2006; 62(Pt 10):1243–1250; doi: 10.1107/S0907444906029799
3.
AusubelFM, BrentR, KingstonR, et al.Current Protocols in Molecular Biology. John Wiley & Sons: New York, NY; 1987.
4.
BroggiA, GranucciF, ZanoniI. Type III interferons: Balancing tissue tolerance and resistance to pathogen invasion. J Exp Med, 2020; 217(1); doi: 10.1084/jem.20190295
5.
BroggiA, TanY, GranucciF, et al.IFN-lambda suppresses intestinal inflammation by non-translational regulation of neutrophil function. Nat Immunol, 2017; 18(10):1084–1093; doi: 10.1038/ni.3821
6.
BuddGT, BukowskiRM, MiketoL, et al.Phase-I trial of UltrapureTM human leukocyte interferon in human malignancy. Cancer Chemother Pharmacol, 1984; 12(1):39–42; doi: 10.1007/BF00255907
7.
CzerkiesM, KochanczykM, KorwekZ, et al.Respiratory syncytial virus protects bystander cells against influenza A virus infection by triggering secretion of type I and type III interferons. J Virol, 2022; 96(22):e0134122; doi: 10.1128/jvi.01341-22
8.
DavidsonS, McCabeTM, CrottaS, et al.IFNlambda is a potent anti-influenza therapeutic without the inflammatory side effects of IFNalpha treatment. EMBO Mol Med, 2016; 8(9):1099–1112; doi: 10.15252/emmm.201606413
9.
de WeerdNA, VivianJP, NguyenTK, et al.Structural basis of a unique interferon-beta signaling axis mediated via the receptor IFNAR1. Nat Immunol, 2013; 14(9):901–907; doi: 10.1038/ni.2667
10.
DickensheetsH, SheikhF, ParkO, et al.Interferon-lambda (IFN-lambda) induces signal transduction and gene expression in human hepatocytes, but not in lymphocytes or monocytes. J Leukoc Biol, 2013; 93(3):377–385; doi: 10.1189/jlb.0812395
11.
DonnellyRP, SheikhF, KotenkoSV, et al.The expanded family of class II cytokines that share the IL-10 receptor-2 (IL-10R2) chain. J Leukoc Biol, 2004; 76(2):314–321; doi: 10.1189/jlb.0204117
12.
DoyleSE, SchreckhiseH, Khuu-DuongK, et al.Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology, 2006; 44(4):896–906; doi: 10.1002/hep.21312
13.
DurocherY, PerretS, KamenA. High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res, 2002; 30(2):E9; doi: 10.1093/nar/30.2.e9
14.
EgliA, SanterDM, O'SheaD, et al.IL-28B is a key regulator of B- and T-cell vaccine responses against influenza. PLoS Pathog, 2014a;10(12):e1004556; doi: 10.1371/journal.ppat.1004556
15.
EgliA, SanterDM, O'SheaD, et al.The impact of the interferon-lambda family on the innate and adaptive immune response to viral infections. Emerg Microbes Infect, 2014b;3(7):e51; doi: 10.1038/emi.2014.51
16.
EvansJG, NovotnyLA, MeissnerEG. Influence of canonical and non-canonical IFNLR1 isoform expression on interferon lambda signaling. Viruses, 2023; 15(3); doi: 10.3390/v15030632
17.
GoelRR, WangX, O'NeilLJ, et al.Interferon lambda promotes immune dysregulation and tissue inflammation in TLR7-induced lupus. Proc Natl Acad Sci U S A, 2020; 117(10):5409–5419; doi: 10.1073/pnas.1916897117
18.
GrodzkiAC, BerensteinE. Antibody purification: Affinity chromatography—protein A and protein G Sepharose. Methods Mol Biol, 2010; 588:33–41; doi: 10.1007/978-1-59745-324-0_5
19.
HammingOJ, Terczynska-DylaE, VieyresG, et al.Interferon lambda 4 signals via the IFNlambda receptor to regulate antiviral activity against HCV and coronaviruses. EMBO J, 2013; 32(23):3055–3065; doi: 10.1038/emboj.2013.232
JilgN, LinW, HongJ, et al.Kinetic differences in the induction of interferon stimulated genes by interferon-alpha and interleukin 28B are altered by infection with hepatitis C virus. Hepatology, 2014; 59(4):1250–1261; doi: 10.1002/hep.26653
22.
KellyA, RobinsonMW, RocheG, et al.Immune cell profiling of IFN-lambda response shows pDCs express hghest level of IFN-lambdaR1 and are directly responsive via the JAK-STAT pathway. J Interferon Cytokine Res, 2016; 36(12):671–680; doi: 10.1089/jir.2015.0169
23.
KotenkoSV, GallagherG, BaurinVV, et al.IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol, 2003; 4(1):69–77; doi: 10.1038/ni875
24.
KotenkoSV, IzotovaLS, MirochnitchenkoOV, et al.Identification of the functional interleukin-22 (IL-22) receptor complex: The IL-10R2 chain (IL-10Rbeta) is a common chain of both the IL-10 and IL-22 (IL-10-related T cell-derived inducible factor, IL-TIF) receptor complexes. J Biol Chem, 2001; 276(4):2725–2732; doi: 10.1074/jbc.M007837200
25.
LutfallaG, GardinerK, ProudhonD, et al.The structure of the human interferon alpha/beta receptor gene. J Biol Chem, 1992; 267(4):2802–2809.
26.
MahlakoivT, HernandezP, GronkeK, et al.Leukocyte-derived IFN-alpha/beta and epithelial IFN-lambda constitute a compartmentalized mucosal defense system that restricts enteric virus infections. PLoS Pathog, 2015; 11(4):e1004782; doi: 10.1371/journal.ppat.1004782
27.
MegjugoracNJ, GallagherGE, GallagherG. Modulation of human plasmacytoid DC function by IFN-lambda1 (IL-29). J Leukoc Biol, 2009; 86(6):1359–1363; doi: 10.1189/jlb.0509347
28.
MordsteinM, NeugebauerE, DittV, et al.Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections. J Virol, 2010; 84(11):5670–5677; doi: 10.1128/JVI.00272-10
29.
NovickD, CohenB, RubinsteinM. The human interferon alpha/beta receptor: Characterization and molecular cloning. Cell, 1994; 77(3):391–400; doi: 0092-8674(94)90154-6[pii]
PestkaS, KrauseCD, SarkarD, et al.Interleukin-10 and related cytokines and receptors. Annu Rev Immunol, 2004; 22:929–979; doi: 10.1146/annurev.immunol.22.012703.104622
32.
PlotnikovaM, LozhkovA, Romanovskaya-RomankoE, et al.IFN-lambda1 displays various levels of antiviral activity in vitro in a select panel of RNA viruses. Viruses, 2021; 13(8); doi: 10.3390/v13081602
33.
Prokunina-OlssonL, MuchmoreB, TangW, et al.A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet, 2013; 45(2):164–171; doi: 10.1038/ng.2521
34.
SanterDM, MintyGES, GolecDP, et al.Differential expression of interferon-lambda receptor 1 splice variants determines the magnitude of the antiviral response induced by interferon-lambda 3 in human immune cells. PLoS Pathog, 2020; 16(4):e1008515; doi: 10.1371/journal.ppat.1008515
35.
SanterDM, MintyGES, MohamedA, et al.A novel method for detection of IFN-lambda 3 binding to cells for quantifying IFN-lambda receptor expression. J Immunol Methods, 2017; 445:15–22; doi: 10.1016/j.jim.2017.03.001
36.
SheppardP, KindsvogelW, XuW, et al.IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol, 2003; 4(1):63–68; doi: 10.1038/ni873
37.
SommereynsC, PaulS, StaeheliP, et al.IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog, 2008; 4(3):e1000017; doi: 10.1371/journal.ppat.1000017
38.
StaniferML, KeeC, CorteseM, et al.Critical role of type III interferon in controlling SARS-CoV-2 infection in human intestinal epithelial cells. Cell Rep, 2020; 32(1):107863; doi: 10.1016/j.celrep.2020.107863
39.
StifterSA, GouldJA, ManganNE, et al.Purification and biological characterization of soluble, recombinant mouse IFNbeta expressed in insect cells. Protein Expr Purif, 2014; 94:7–14; doi: 10.1016/j.pep.2013.10.019
40.
ThulPJ, AkessonL, WikingM, et al.A subcellular map of the human proteome. Science, 2017; 356(6340); doi: 10.1126/science.aal3321
41.
TomR, BissonL, DurocherY. Transfection of HEK293-EBNA1 cells in suspension with 293fectin for production of recombinant proteins. CSH Protoc, 2008; 2008:pdb prot4979; doi: 10.1101/pdb.prot4979
42.
WitteK, GruetzG, VolkHD, et al.Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: Implications for therapeutic applications of these cytokines. Genes Immun, 2009; 10(8):702–714; doi: 10.1038/gene.2009.72
43.
YinZ, DaiJ, DengJ, et al.Type III IFNs are produced by and stimulate human plasmacytoid dendritic cells. J Immunol, 2012; 189(6):2735–2745; doi: 10.4049/jimmunol.1102038
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
